Clazakizumab
Clazakizumab is an investigational, humanized rabbit-derived monoclonal antibody that blocks interleukin-6 (IL-6), a protein involved in inflammation. It was developed by Bristol Myers Squibb and Alder Biopharmaceuticals and is also known as ALD518 or BMS-945429. The drug is given by infusion. In a phase 2 trial for psoriatic arthritis, clazakizumab showed potential to help musculoskeletal symptoms, but there was no clear dose‑response relationship.
This page was last edited on 3 February 2026, at 08:46 (CET).